|
|
 Previous Article | Table of Contents | Next Article 
Association of erythrodermic cutaneous T-cell lymphoma, superantigen-
positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene
expansion
CM Jackow, JC Cather, V Hearne, AT Asano, JM Musser and M Duvic
Department of Dermatology, University of Texas Medical School, Houston,
USA.
Forty-two patients with cutaneous T-cell lymphoma, including 31 with
exfoliative erythroderma or Sezary syndrome and 11 with mycosis fungoides,
were studied for the occurrence of staphylococcal infection. Thirty-two of
42 (76%) had a positive staphylococcal culture from skin or blood. One half
of the patients with positive cultures grew Staphylococcus aureus. This
group included 11 with Sezary syndrome and 5 with rapidly enlarging mycosis
fungoides plaques or tumors. All of the S aureus carried enterotoxin genes.
Surprisingly, 6 of 16 strains were the same toxic shock toxin-1
(TSST-1)-positive clone, designated electrophoretic type (ET)-41. Analysis
of the T-cell receptor V beta repertoire in 14 CTCL patients found that
only 4 had the expected monoclonal expansion of a specific V beta gene,
whereas 10 had oligoclonal or polyclonal expansion of several V beta
families. All patients with TSST-1+ S aureus had overexpansion of V beta Z
in blood and/or skin lesions. These studies show that S aureus containing
superantigen enterotoxins are commonly found in patients with CTCL
especially individuals with erythroderma where they could exacerbate and/or
perpetuate stimulate chronic T-cell expansion and cutaneous inflammation.
Attention to toxigenic S aureus in CTCL patients would be expected to
improve the quality of care and outcome of this patient population.
Volume 89,
Issue 1,
pp. 32-40,
01/01/1997
Copyright © 1997 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Olsen, E. Vonderheid, N. Pimpinelli, R. Willemze, Y. Kim, R. Knobler, H. Zackheim, M. Duvic, T. Estrach, S. Lamberg, et al.
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
Blood,
September 15, 2007;
110(6):
1713 - 1722.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Woetmann, P. Lovato, K. W. Eriksen, T. Krejsgaard, T. Labuda, Q. Zhang, A.-M. Mathiesen, C. Geisler, A. Svejgaard, M. A. Wasik, et al.
Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins
Blood,
April 15, 2007;
109(8):
3325 - 3332.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Duvic, R. Talpur, X. Ni, C. Zhang, P. Hazarika, C. Kelly, J. H. Chiao, J. F. Reilly, J. L. Ricker, V. M. Richon, et al.
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
Blood,
January 1, 2007;
109(1):
31 - 39.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Ortonne, D. Huet, C. Gaudez, A. Marie-Cardine, V. Schiavon, M. Bagot, P. Musette, and A. Bensussan
Significance of circulating T-cell clones in Sezary syndrome
Blood,
May 15, 2006;
107(10):
4030 - 4038.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-i. Yamanaka, N. Yawalkar, D. A. Jones, D. Hurwitz, K. Ferenczi, S. Eapen, and T. S. Kupper
Decreased T-Cell Receptor Excision Circles in Cutaneous T-Cell Lymphoma
Clin. Cancer Res.,
August 15, 2005;
11(16):
5748 - 5755.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Herling, J. D. Khoury, L. T. Washington, M. Duvic, M. J. Keating, and D. Jones
A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories
Blood,
July 15, 2004;
104(2):
328 - 335.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
CD30+ Cutaneous Lymphoma in Association With Atopic Eczema
Arch Dermatol,
April 1, 2004;
140(4):
449 - 454.
|
|
|
|
|
|
|
N. Yawalkar, K. Ferenczi, D. A. Jones, K. Yamanaka, K.-Y. Suh, S. Sadat, and T. S. Kupper
Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma
Blood,
December 1, 2003;
102(12):
4059 - 4066.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Herne, R. Talpur, J. Breuer-McHam, R. Champlin, and M. Duvic
Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sezary syndrome
Blood,
March 15, 2003;
101(6):
2132 - 2135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Vega, R. Luthra, L. J. Medeiros, V. Dunmire, S.-J. Lee, M. Duvic, and D. Jones
Clonal heterogeneity in mycosis fungoides and its relationship to clinical course
Blood,
October 16, 2002;
100(9):
3369 - 3373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ingen-Housz-Oro, A. Bussel, B. Flageul, L. Michel, L. Dubertret, P. Kourilsky, G. Gachelin, H. Bachelez, and P. Musette
A prospective study on the evolution of the T-cell repertoire in patients with Sezary syndrome treated by extracorporeal photopheresis
Blood,
August 28, 2002;
100(6):
2168 - 2174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Ni, P. Hazarika, C. Zhang, R. Talpur, and M. Duvic
Fas Ligand Expression by Neoplastic T Lymphocytes Mediates Elimination of CD8+ Cytotoxic T Lymphocytes in Mycosis Fungoides: A Potential Mechanism of Tumor Immune Escape?
Clin. Cancer Res.,
September 1, 2001;
7(9):
2682 - 2692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Burg, R. Dummer, A. Haeffner, W. Kempf, and M. Kadin
From Inflammation to Neoplasia: Mycosis Fungoides Evolves From Reactive Inflammatory Conditions (Lymphoid Infiltrates) Transforming Into Neoplastic Plaques and Tumors
Arch Dermatol,
July 1, 2001;
137(7):
949 - 952.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Duvic, K. Hymes, P. Heald, D. Breneman, A. G. Martin, P. Myskowski, C. Crowley, and R. C. Yocum
Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results
J. Clin. Oncol.,
May 1, 2001;
19(9):
2456 - 2471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Duvic, A. G. Martin, Y. Kim, E. Olsen, G. S. Wood, C. A. Crowley, R. C. Yocum, and for the Worldwide Bexarotene Study Group
Phase 2 and 3 Clinical Trial of Oral Bexarotene (Targretin Capsules) for the Treatment of Refractory or Persistent Early-Stage Cutaneous T-Cell Lymphoma
Arch Dermatol,
May 1, 2001;
137(5):
581 - 593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Siegel, T. Pandolfino, J. Guitart, S. Rosen, and T. M. Kuzel
Primary Cutaneous T-Cell Lymphoma: Review and Current Concepts
J. Clin. Oncol.,
August 15, 2000;
18(15):
2908 - 2925.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Abrams, E. C. Vonderheid, S. Kolbe, D. M. Appelt, E. J. Arking, and B. J. Balin
Sezary T-Cell Activating Factor Is a Chlamydia pneumoniae-Associated Protein
Clin. Vaccine Immunol.,
November 1, 1999;
6(6):
895 - 905.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ladhani, C. L. Joannou, D. P. Lochrie, R. W. Evans, and S. M. Poston
Clinical, Microbial, and Biochemical Aspects of the Exfoliative Toxins Causing Staphylococcal Scalded-Skin Syndrome
Clin. Microbiol. Rev.,
April 1, 1999;
12(2):
224 - 242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B.-N. Lee, M. Duvic, C.-K. Tang, C. Bueso-Ramos, Z. Estrov, and J. M. Reuben
Dysregulated Synthesis of Intracellular Type 1 and Type 2 Cytokines by T Cells of Patients with Cutaneous T-Cell Lymphoma
Clin. Vaccine Immunol.,
January 1, 1999;
6(1):
79 - 84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Musette, H. Bachelez;, C. M. Jackow, and M. Duvic
Cutaneous T-Cell Lymphomas and Bacterial Superantigens
Blood,
July 1, 1997;
90(1):
472 - 473.
[Full Text]
[PDF]
|
|
|
|
|
